CN101371843B - 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 - Google Patents
洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 Download PDFInfo
- Publication number
- CN101371843B CN101371843B CN2008101336457A CN200810133645A CN101371843B CN 101371843 B CN101371843 B CN 101371843B CN 2008101336457 A CN2008101336457 A CN 2008101336457A CN 200810133645 A CN200810133645 A CN 200810133645A CN 101371843 B CN101371843 B CN 101371843B
- Authority
- CN
- China
- Prior art keywords
- loxapine
- purposes
- administration
- aerosol
- headache
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960000423 loxapine Drugs 0.000 title claims abstract description 122
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 title claims abstract description 122
- 239000003814 drug Substances 0.000 title claims description 57
- 208000002193 Pain Diseases 0.000 title abstract description 69
- 229960002519 amoxapine Drugs 0.000 title abstract description 68
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 title abstract description 68
- 230000036407 pain Effects 0.000 title abstract description 66
- 238000002360 preparation method Methods 0.000 title description 14
- 206010019233 Headaches Diseases 0.000 claims abstract description 38
- 231100000869 headache Toxicity 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 206010027599 migraine Diseases 0.000 claims abstract description 22
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 20
- 208000006561 Cluster Headache Diseases 0.000 claims abstract description 5
- 206010043269 Tension headache Diseases 0.000 claims abstract description 5
- 208000008548 Tension-Type Headache Diseases 0.000 claims abstract description 5
- 239000000443 aerosol Substances 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 206010018873 Haemoconcentration Diseases 0.000 claims description 6
- 239000010408 film Substances 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 6
- 239000010409 thin film Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000007857 degradation product Substances 0.000 claims description 2
- 238000006068 polycondensation reaction Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 abstract description 10
- 229940002612 prodrug Drugs 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 238000011160 research Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 239000000935 antidepressant agent Substances 0.000 description 19
- 229940005513 antidepressants Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- -1 1-piperazinyl Chemical group 0.000 description 13
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
- 208000028017 Psychotic disease Diseases 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960005181 morphine Drugs 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
- 229960000836 amitriptyline Drugs 0.000 description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 229960005426 doxepin Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004442 gravimetric analysis Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocorninine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010054956 Phonophobia Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002146 guaifenesin Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960004572 pizotifen Drugs 0.000 description 2
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- OJCPSBCUMRIPFL-UHFFFAOYSA-N prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000607 toxicokinetics Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- VZVRZTZPHOHSCK-YVLHZVERSA-N (3z)-3-(12h-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-n,n-dimethylpropan-1-amine Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=C1C1=CC=CC=C1O2 VZVRZTZPHOHSCK-YVLHZVERSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PTUSXMWNCXRKAX-UHFFFAOYSA-N 2-(1h-inden-1-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)C=CC2=C1 PTUSXMWNCXRKAX-UHFFFAOYSA-N 0.000 description 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 1
- IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 description 1
- IUZXQGCIJLIGLS-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-2-phenyl-2,3-dihydro-1,5-benzothiazepin-4-one;hydron;chloride Chemical compound Cl.C1C(=O)N(CCN(C)C)C2=CC=CC=C2SC1C1=CC=CC=C1 IUZXQGCIJLIGLS-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029915 Maxillary disease Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 1
- 229960003148 adinazolam Drugs 0.000 description 1
- 229960002820 adrafinil Drugs 0.000 description 1
- CGNMLOKEMNBUAI-UHFFFAOYSA-N adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- YDOTUXAWKBPQJW-UHFFFAOYSA-N alpha-Ergocryptinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-NSLWYYNWSA-N alpha-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-NSLWYYNWSA-N 0.000 description 1
- 229950001817 alpha-ergocryptine Drugs 0.000 description 1
- QRQMZZNDJGHPHZ-UHFFFAOYSA-N alpiropride Chemical compound C1=C(N)C(S(=O)(=O)NC)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC QRQMZZNDJGHPHZ-UHFFFAOYSA-N 0.000 description 1
- 229950002006 alpiropride Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002980 amitriptyline oxide Drugs 0.000 description 1
- ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004191 axillary artery Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960001498 benactyzine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- QTNZYVAMNRDUAD-UHFFFAOYSA-N butacetin Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 1
- 229950011189 butacetin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004301 butriptyline Drugs 0.000 description 1
- ALELTFCQZDXAMQ-UHFFFAOYSA-N butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
- 108010066114 cabin-2 Proteins 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
- 229950006044 caroxazone Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 description 1
- 229950010189 demexiptiline Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- HGKAMARNFGKMLC-RBUKOAKNSA-N dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 description 1
- 229960003075 dibenzepin Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960003524 dimetacrine Drugs 0.000 description 1
- RYQOGSFEJBUZBX-UHFFFAOYSA-N dimetacrine Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 RYQOGSFEJBUZBX-UHFFFAOYSA-N 0.000 description 1
- CMKUGKVVUUGBHJ-UHFFFAOYSA-N dimethazan Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(C)C CMKUGKVVUUGBHJ-UHFFFAOYSA-N 0.000 description 1
- 229950002134 dimethazan Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229960001640 dimetotiazine Drugs 0.000 description 1
- VWNWVCJGUMZDIU-UHFFFAOYSA-N dimetotiazine Chemical compound C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 VWNWVCJGUMZDIU-UHFFFAOYSA-N 0.000 description 1
- 229950006161 dioxadrol Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229950010344 donitriptan Drugs 0.000 description 1
- SOHCKWZVTCTQBG-UHFFFAOYSA-N donitriptan Chemical compound C1=C2C(CCN)=CNC2=CC=C1OCC(=O)N(CC1)CCN1C1=CC=C(C#N)C=C1 SOHCKWZVTCTQBG-UHFFFAOYSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- XQUUDUKVJKNJNP-OGGGUQDZSA-N ergocornine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3C1=C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XQUUDUKVJKNJNP-OGGGUQDZSA-N 0.000 description 1
- UJYGDMFEEDNVBF-XJUOHTAZSA-N ergocorninine Chemical compound C1=CC(C=2[C@@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-XJUOHTAZSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- QHZQILHUJDRDAI-UHFFFAOYSA-N febarbamate Chemical compound O=C1N(CC(COCCCC)OC(N)=O)C(=O)NC(=O)C1(CC)C1=CC=CC=C1 QHZQILHUJDRDAI-UHFFFAOYSA-N 0.000 description 1
- 229960005182 febarbamate Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- PDTADBTVZXKSJM-UHFFFAOYSA-N fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- SNJDSTGQYRTZJT-UHFFFAOYSA-N fenpentadiol Chemical compound CC(C)(O)CC(C)(O)C1=CC=C(Cl)C=C1 SNJDSTGQYRTZJT-UHFFFAOYSA-N 0.000 description 1
- 229950011196 fenpentadiol Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003441 imipramine oxide Drugs 0.000 description 1
- QZIQORUGXBPDSU-UHFFFAOYSA-N imipramine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- 229960002589 iproclozide Drugs 0.000 description 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229950007692 lomerizine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229960004794 melitracen Drugs 0.000 description 1
- GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 description 1
- 229950006180 metapramine Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- GVXBHSBKKJRBMS-UHFFFAOYSA-N metralindole Chemical compound C1CN(C)C2=NCCC3=C2N1C1=CC=C(OC)C=C13 GVXBHSBKKJRBMS-UHFFFAOYSA-N 0.000 description 1
- 229950006787 metralindole Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960004758 minaprine Drugs 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- GPTURHKXTUDRPC-UHFFFAOYSA-N noxiptiline Chemical compound C1CC2=CC=CC=C2C(=NOCCN(C)C)C2=CC=CC=C21 GPTURHKXTUDRPC-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- FODQIVGFADUBKE-UHFFFAOYSA-N octamoxin Chemical compound CCCCCCC(C)NN FODQIVGFADUBKE-UHFFFAOYSA-N 0.000 description 1
- 229950006863 octamoxin Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960005290 opipramol Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229960002019 oxaflozane Drugs 0.000 description 1
- FVYUQFQCEOZYHZ-UHFFFAOYSA-N oxaflozane Chemical compound C1N(C(C)C)CCOC1C1=CC=CC(C(F)(F)F)=C1 FVYUQFQCEOZYHZ-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960003544 oxetorone Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- TZFUBYYADABEAV-UHFFFAOYSA-N piberaline Chemical compound C=1C=CC=NC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 TZFUBYYADABEAV-UHFFFAOYSA-N 0.000 description 1
- 229950009306 piberaline Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960004654 prolintane Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- YFLBETLXDPBWTD-UHFFFAOYSA-N propizepine Chemical compound O=C1N(CC(C)N(C)C)C2=CC=CC=C2NC2=NC=CC=C21 YFLBETLXDPBWTD-UHFFFAOYSA-N 0.000 description 1
- 229950003857 propizepine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960000279 quinupramine Drugs 0.000 description 1
- JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 239000010458 rotten stone Substances 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- JJSHYECKYLDYAR-UHFFFAOYSA-N thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- PNYKGCPSFKLFKA-UHFFFAOYSA-N tofenacin Chemical compound C=1C=CC=C(C)C=1C(OCCNC)C1=CC=CC=C1 PNYKGCPSFKLFKA-UHFFFAOYSA-N 0.000 description 1
- 229950010076 tofenacin Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
本发明涉及洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用。洛沙平、阿莫沙平或两者之一的盐或前药在减轻疼痛,尤其是头痛,例如偏头痛、丛集性头痛和紧张性头痛方面是有效的。优选地,洛沙平或阿莫沙平被全身给药,最优选通过吸入给药。
Description
本申请是申请日为2003年11月20日,中国国家申请号为200380104151.1,发明题目为“洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用”的分案申请。
发明背景
本发明涉及,通过给有这种治疗或控制需求的患者服用有效量的洛沙平或阿莫沙平、或在体内提供洛沙平或阿莫沙平的物质治疗和控制疼痛。进一步地,本发明涉及通过全身给予(例如通过吸入)洛沙平、阿莫沙平、或在体内提供洛沙平或阿莫沙平的物质治疗或控制疼痛。
洛沙平[2-氯-11(4-甲基-1-哌嗪基)二苯(b,f)(1,4)氧氮杂]是一种抗精神病药,尤其用于治疗精神分裂症或相关精神病。它以盐,通常是盐酸盐或琥珀酸盐的形式供商购。阿莫沙平[2-氯-11(1-哌嗪基)二苯(b,f)(1,4)氧氮杂]是已知的抗抑郁药,它区别于其它的抗抑郁药在于它既具有抗抑郁效力,又具有抗精神病效力。因此,阿莫沙平不同于其它抗抑郁药,主要用于治疗精神病性抑郁症。
一些专利和文献指出,选择性抗精神病药和/或抗抑郁药可在一定程度上治疗疼痛。然而,支持这些推测的数据是分散和不稳定的,一些药物显示了不同程度控制疼痛的一些能力,而相同药理学类别的其它化合物在疼痛控制方面却完全无效。因此,没有真正全面的模式出现。
例如,美国专利5,929,070、5,945,416和6,258,807公开了单独或联合使用奥氮平治疗各种类型的疼痛。美国专利6,444,665公开了使用各种非典型性抗精神病化合物,也就是利培酮、氯氮平、喹硫平、舍吲哚、齐拉西酮和佐替平来治疗疼痛,尤其是当和许多其它疼痛缓解药一起给药时。另一方面,另一项研究[Schreiber等人,(1999)Pharmacology Biochemistry Behavior 64:75]和文献指出,非典型性抗精神病药,即使是同类(例如奥氮平和氯氮平)之间,在它们控制疼痛的能力方面存在区别,从而证明了镇痛作用不是抗精神病药物的同类效果。
美国专利6,290,986公开了以含卵磷脂有机凝胶的特定制剂透皮给予各种药物以控制局部疼痛。公开了用于这种制剂的一些抗抑郁药,特别是阿米替林和多塞平。然而,那些抗抑郁药只主张了仅与愈创甘油醚——一种已知其本身具有镇痛效果的化合物——联用有效的权利要求,当不与愈创甘油醚一起给药时,没有迹象显示抗抑郁药有效。在专利文本的末尾表达了一种“信心”,那就是许多其它三环类药物包括阿莫沙平会显示出类似的活性。在同一系列的较晚专利第6,479,074号中,阿莫沙平被包括在三环类化合物的名单中,据说能用在某些透皮组合物中治疗局部疼痛,再次与愈创甘油醚联合给药。然而,没有报道阿莫沙平的数据。类似地,美国专利6,638,981声称,由于它们的局部麻醉作用,通过使用局部施用的组合物,含抗抑郁药的组合物在治疗局部疼痛中是有效的。然而,那篇专利中没有提到全身给药后抗抑郁药的镇痛效果。提到了十类抗抑郁药,包括各种或“所有”类别。每一类都包括据推测具有镇痛活性的大量化合物。阿莫沙平被列在其中一个种类的其它大量化合物中,但仍然没有给出数据,或者实际上,该专利中单独命名的大部分化合物都没有给出。相反地,数据集中在两个化合物——阿米替林和氯胺酮上。美国专利5,900,249和6,211,171也在据说当掺入局部组合物(例如作为局麻剂)时能用于控制疼痛的大量化合物中提到了阿莫沙平,但仍然没有给出阿莫沙平的数据,也没有提出全身给药后抗抑郁药的镇痛效果。
Lynch,[″Antidepressants as analgesics:a review ofrandomi zed controlled trials″(2001)Revue de Psychiatre et deNeuroscience 26:30],总结了调查抗抑郁药的镇痛效果的59个随机的安慰剂-对照试验的结果后得出:“有重要证据表明,三环类抗抑郁药能镇痛,而曲唑酮却不能;关于选择性5-羟色胺再摄取抑制剂的数据是矛盾的。”然而,即使对于三环类抗抑郁药来说,所引用的41篇文献也仅研究了5个这样的化合物(阿米替林、多塞平、丙米嗪、氯米帕明和地昔帕明),并没有包括洛沙平或阿莫沙平的任何报告,其显著地区别于试验了作用机制的化合物。
简言之,少数抗抑郁药已经显示出具有某种镇痛性质,主要是当作为局部或透皮组合物施用时,来控制局部疼痛或提供局部麻醉。然而,这些化合物的效力与它们的抗抑郁活性无关,并且没有显示出代表一类效果的任何类型。而且,同时另一项研究[Hamon等人,(1987)Neuropharmacology 26:531-539]显示,用阿莫沙平持续处理动物模型以后,吗啡的镇痛效果被增强了,结果指出,阿莫沙平本身对疼痛没有效果。那篇文献的图1显示,阿莫沙平单独持续给药后,甩尾的潜伏期没有改变,从而指出阿莫沙平单独对疼痛基本没有效果。在另一篇文献中,Pfeiffer[(1982)Geriatrics 27:67]声明,某些三环类抗抑郁药包括阿莫沙平“对于出现疼痛作为抑郁躯体化的患者给出了很好的结果”。这些抗抑郁药被用于治疗表现为疼痛的抑郁躯体化而不用于真正疼痛再次得到了区分。
简言之,(在一些上述专利中),阿莫沙平已经被列在了据认为具有某些这种活性的大量化合物中,但没有给出数据证明它具有这种能力,而且一项研究显示缺乏这种活性。另外,与提出使用抗精神病药可减轻疼痛的文献相反,一些抗精神病药已经已经确切显示出产生了相反的作用——增加疼痛[参见Frussa-Filho等人,(1996)ArchInt Pharmacodyn 331:74-93(haloperidol)和Gleeson等人(1982).Psychopharmacology 78:141-146(chlorpromazine)]。从这些极少量信息中不能确定阿莫沙平控制疼痛尤其是非局部化疼痛的能力(如果有的话),而且现有技术中没有关于洛沙平是否具有任何性质的任何疼痛控制效果的信息。
发明简述
本发明包括通过全身或向脑部给予有效量的洛沙平或阿莫沙平治疗或控制疼痛。优选地,通过吸入给予洛沙平或阿莫沙平。本发明也包括如上给予洛沙平或阿莫沙平治疗疼痛的方法,以及用于如此给药的制剂。
附图简述
图1是点图,显示了以2mg/kg剂量通过吸入给小猎犬施用洛沙平开始后,各小时的洛沙平血浆浓度(ng/mL)。
图2是点图,显示了以0.2mg/kg剂量通过吸入对小猎犬施用洛沙平开始后,各小时的洛沙平血浆浓度(ng/mL)。
发明详述
洛沙平[2-氯-11(4-甲基-1-哌嗪基)二苯(b,f)(1,4)氧氮杂]是一种抗精神病药,尤其用于治疗精神分裂症或相关精神病。它以盐,通常是盐酸盐或琥珀酸盐的形式供商购。阿莫沙平[2-氯-11(1-哌嗪基)二苯(b,f)(1,4)氧氮杂]是已知的具有抗精神病性质的抗抑郁药。
洛沙平或阿莫沙平在疼痛的治疗或控制中都未曾显示有效。然而我们已经发现,这些物质在治疗或控制疼痛方面出人意料地有效,特别是头痛,包括偏头痛、紧张性头痛和丛集性头痛。
本发明疼痛的治疗或控制是通过给予有这种治疗需求的患者疼痛减轻或疼痛缓解有效量的阿莫沙平、洛沙平、它们两者之一的可药用盐、或它们两者之一的前药来实现的。使用这些活性成分的盐或前药可以为给患者分别提供适当量的洛沙平或阿莫沙平提供有效的方法,可在制备、包装,或另外在制备和/或对活性成分给药方面提供有利条件。
本发明的一个方面是,将疼痛减轻有效量的洛沙平或阿莫沙平,或洛沙平或阿莫沙平的可药用盐或前药给药来治疗病人或患者。“疼痛减轻有效量”指的是正讨论的压制或抑制疼痛的物质的量。本发明既可用于减轻已存在的疼痛,也可用于压制或抑制来自即将发生的疼痛引发事故的必然发生的疼痛。
术语“减轻”、“压制”和“抑制”是成功治疗或减轻疼痛的标记,包括客观和主观参数例如症状的减轻、消除,使病人或患者对疼痛症状或状况更能容忍,减少疼痛的持续时间或减少有可能在事故后出现的疼痛的发作。当指的是治疗头痛,包括偏头痛时,术语“减轻”、“压制”和“抑制”是成功治疗或减轻任何已存在的头痛或头痛的任何先兆的标记,包括客观和主观参数例如症状的减轻、消除,使病人或患者对头痛更能容忍,减少头痛的持续时间或减少预期的尾随头痛先兆而发生的头痛,并明确排除降低疼痛(头痛)的发生频率或预防疼痛(头痛)的发生,除非当这种频率的降低或这种发作的预防通过使用药物可达到,特别是在头痛先兆过程中或在头痛本身的首次征兆时,因此,当指头痛的治疗时,术语“减轻”、“压制”和“抑制”明确排除持续使用药物用于头痛预防的目的。
如此处所用的,“疼痛”包括所有类型的疼痛。该术语包括的更明确的疼痛类型包括神经性疼痛、炎性痛、伤害性疼痛、急性痛、慢性痛、区域性疼痛、全身疼痛、术后疼痛、牙痛、偏头痛、丛集性头痛、紧张性头痛、神经痛、癌痛、抵抗性疼痛、灼伤所致疼痛、阵痛和分娩痛、产后疼痛、肠应激综合征、纤维肌痛、胰痛、心肌梗塞痛和颞-上颌疾病(temporal-mandibulla disorders)。本发明特别适用的是通过接近中枢神经系统,尤其是通过全身给予有效量的洛沙平或阿莫沙平或两者之一的盐或前药来治疗偏头痛、丛集性头痛和紧张性头痛,以及其它类型的疼痛。
术语“患者”或“病人”指的是脊椎动物,优选是哺乳动物,包括灵长类哺乳动物例如人类及其它哺乳动物,包括非灵长类哺乳动物例如宠物、家畜等。
术语“可药用盐”包括活性化合物的盐,其是用相关的无毒酸制备的,这取决于此处描述的化合物上发现的特定取代基。“可药用”的意思是正在讨论的盐是或者可以被联邦、州或其它外国政府的管理机构所批准,或者被列在美国药典或用于动物尤其是人类的其它通常认可的药典中。由于本发明化合物包含相对碱性的官能团,可以通过将这些化合物的中性形式与足量的需要的酸在不含水的或适当的惰性溶剂中接触来制备酸加成盐。可药用酸加成盐的例子包括那些衍生自无机酸如盐酸、氢溴酸、硝酸、碳酸、一氢碳酸、磷酸、一氢磷酸、二氢磷酸、硫酸、一氢硫酸、氢碘酸或亚磷酸等的盐,以及衍生自相关的无毒有机酸如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、富马酸、乳酸、扁桃酸、酞酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸或甲磺酸等的盐。还包括在内的是氨基酸盐,例如精氨酸盐等,以及有机酸如葡萄糖醛酸或半乳糖醛酸等的盐(参见例如Berge等人,″Pharmaceutical Salts″,Journal ofPharmaceutical Science,1977,66,1-19)。
从盐开始,化合物的中性形式可通过将盐与碱(或酸)接触,并用常规方法分离母体化合物来重建。化合物的母体形式与各种盐的形式在某些物理性质上有区别,例如极性溶剂中的溶解度,然而就本发明目的来说,盐却相当于化合物的母体形式。
除了盐的形式,本发明还提供前药形式的活性化合物。此处描述的化合物前药是在化学、生化或生理条件下很容易进行化学改变分别生成洛沙平或阿莫沙平的那些化合物。例如,洛沙平或阿莫沙平的前药包括在生物学条件下,在体外或体内可被水解、氧化、氢化、裂解或反应以产生活性化合物的那些化合物。洛沙平的一些膦酰氧甲基前药公开在Krise等人,J Pharm Sci.(1999)88:922和928以及J MedChem.(1999)42:3094中。
当用于治疗患者以减轻疼痛尤其是治疗偏头痛时,洛沙平或阿莫沙平所采用的剂量通常分别低于它们目前分别治疗精神分裂症和抑郁目的时的剂量。
如内科医生案头参考资料(第57版,2003年)中所描述的,治疗精神分裂症时推荐的洛沙平初始口服剂量是10-20mg/天,分2-4次给药。然而,该剂量通常无效,据测定一般的口服剂量是20-100mg/天,通常是60-100mg,至多250mg。通常的单次顿服(single acute)剂量是20-50mg。治疗严重精神障碍(主要是精神分裂症)时,洛沙平的通常肌内给药日剂量是50-150mg——口服给药时总剂量一般分成2-4个剂量。基于包含洛沙平产品的制造商[Lederle实验室]所进行的研究,口服给药后Tmax是2-3小时。有关口服给药后Cmax的信息是颇受争议的,源于两项研究的互相矛盾的报告。根据一项研究,25mg口服剂量以后,洛沙平及其代谢物的Cmax是~0.35μg/ml。然而,根据另一项研究,25mg口服剂量以后,洛沙平本身的Cmax是~10-12ng/ml。还没有确切的肌内制剂的PK研究。然而,行为观察表明,吸收相对缓慢。
然而,为了根据本发明治疗偏头痛,洛沙平的给药剂量是大约0.3到大约20mg每单位剂量,优选大约1到大约10mg,更优选大约2到大约6mg。一般地,在偏头痛发作时的单次剂量是有效的,没有必要每天给予多剂量。本发明的某些实施方案中,上述剂量是作为一系列较小剂量来给予的,直至实现偏头痛缓解。
治疗抑郁时,阿莫沙平的通常口服日剂量是200-400mg。治疗通常是从50mg口服剂量、每天给药3次开始的(也就是总的日剂量是150mg),剂量逐渐增加。100mg口服给药后,阿莫沙平的Tmax是~1.5小时。相同剂量给药后,Cmax是~50ng/ml[Calvo等人,Int J ClinPharmacol Ther Toxicol(1985)23:180]。最低使用口服剂量(50mg)后,Cmax是~30ng/ml[Jue等人,Drugs(1982)24:1]。重复阿莫沙平给药后,存在活性药物的蓄集-血液浓度是~30-300ng/ml(Calvo等人1985)。
然而,对于根据本发明治疗偏头痛来说,阿莫沙平的给药剂量是大约3到大约100mg每单次剂量,优选大约10到大约40mg。
含洛沙平或阿莫沙平的组合物可以任何能够全身给药的方式给予病人或患者。这包括吸入给药,胃肠外给药,例如注射(例如皮内、肌内、腹膜内、静脉内、鞘内或皮下)和粘膜给药(例如鼻内、口腔或直肠途径)。在本发明的优选实施方案中,含洛沙平或阿莫沙平的药物组合物是通过吸入或注射,或粘膜给药的,包括但并不限于鼻腔、舌下(或其它口腔给药)、肺(也就是吸入到肺里,例如通过吸入器或喷雾器)和直肠给药。其活性成分可单独给药或与其它生物活性剂一起给药,例如像本部分中描述的那样。给药可以是全身的或局部的,但优选全身的。如果是局部的,给药优选经由鼻子直接给到脑部,而没有药物首先进入全身循环。药物经由鼻子这样进入脑部可发生在药物经由嗅束内的细胞外间隙通过。
本发明的药物组合物被制成与如上所述的计划的给药途径相符。如本领域已知的,不同类型的组合物通常被制成用于不同的给药途径。一般地,组合物会包含各种赋形剂、添加剂和用于例如储存稳定、易于给药等目的的辅剂。
例如,静脉内给药组合物或其它注射剂通常是无菌等渗水性缓冲液的溶液。如果需要的话,组合物也可包含增溶剂和局麻剂例如利多卡因,以在注射部位减轻疼痛。
如果本发明的组合物准备口服给药,它们可以制成例如片剂、胶囊、扁胶囊、软胶囊、溶液或混悬液等形式。片剂或胶囊可通过传统方法,用可药用赋形剂例如粘合剂(例如预凝胶化玉米淀粉、聚乙烯吡咯烷酮或羟丙甲基纤维素)、填充剂(例如乳糖、微晶纤维素或磷酸氢钙)、润滑剂(例如硬脂酸镁、滑石或硅土)、崩解剂(例如马铃薯淀粉或羟基乙酸淀粉钠)或润湿剂(例如硫酸月桂酯钠)来制备。片剂可用本领域熟知的方法包衣。口服给药的液体制剂可以是例如溶液、糖浆或混悬液的形式,或可制成干粉产品,使用前用水或其它合适的赋形剂重构。这种液体制剂可通过传统方法,用可药用添加剂例如助悬剂(例如山梨糖醇糖浆、纤维素衍生物或氢化食用脂肪)、乳化剂(例如卵磷脂或阿拉伯胶)、非水载体(例如杏仁油、油酯、乙醇或分馏植物油)和防腐剂(例如对羟基苯甲酸甲酯或丙酯或山梨酸)来制备。制剂也可包含适当的缓冲盐、调味剂、着色剂和甜味剂。口服给药制剂可被适当地制备用,以缓释、控释或持续释放预防剂或治疗剂。
本发明组合物也可被制成通过注射的胃肠外给药剂型,例如通过快速静脉注射或持续输注。注射剂型可呈单位剂量形式,例如装在安瓿或多剂量容器中,含另外的防腐剂。组合物可以是这些形式例如油性或水性赋形剂中的混悬剂、溶液或乳液,可含添加剂例如助悬剂、稳定剂和/或分散剂。或者,活性成分可以是干粉形式,在使用前用适当赋形剂例如无菌无热源水重构。
如果本发明组合物是通过鼻腔粘膜给药,组合物可以制成气雾剂形式、喷雾、薄雾或液滴形式。特别地,可以以加压包装或喷雾器中的气雾剂喷雾的形式方便地递送本发明组合物,使用适当的推进剂,例如二氯二氟甲烷、三氯氟甲烷、二氯四氟甲烷、二氧化碳或其它合适的气体。对于加压气雾剂来说,通过提供阀来递送经计量的量可确定剂量单位。用在吸入器或吹入器中的例如明胶的胶囊和药筒可被制成包含化合物和适当的粉末基质例如乳糖或淀粉的粉末混合物。
本发明组合物也可制成直肠组合物例如栓剂或滞留灌肠剂,例如包含传统的栓剂基质例如可可油或其它甘油酯。
本发明组合物也可制成经皮给药。经皮给药时,活性化合物被制成本领域一般公知的软膏、油膏、凝胶或乳膏。适于经皮给药的药物组合物可制成单独的贴剂,与表皮密切接触一段延长的时间。如果本发明组合物是局部给药,组合物可制成例如软膏、乳膏、透皮贴剂、洗剂、凝胶、喷雾、气雾剂、溶液、乳液或本领域技术人员熟知的其它剂型的形式。对于不可喷射的局部剂型,通常采用包含与局部施用相容的、具有动态粘度、优选比水大的粘度的载体或一种或多种赋形剂的粘稠至半固体或固体形式。合适的制剂包括但并不限于溶液、混悬液、乳液、乳膏、软膏、粉末、搽剂或油膏等,如果需要的话,它是灭菌的,或与辅剂(例如防腐剂、稳定剂、润湿剂、缓冲液或盐)相混和,以影响各种性质例如渗透压。其它合适的局部剂型包括可喷射的气雾剂,其中,活性成分(优选与固体或液体惰性载体联用)被包装在有加压挥发物(例如气体抛射剂例如氟利昂)的混和器中,或塑料挤瓶中。如果需要的话,增湿剂或保湿剂也可加到药物组合物和剂型中。这种添加成分的例子是本领域熟知的。
本发明组合物也可制成贮库制剂。这种长效制剂可通过植入(例如皮下或肌内)给药或通过肌内注射给药。因此,组合物可与例如适当的聚合物或疏水材料(例如溶于可接受的油的乳剂)或离子交换树脂一起制备,或者作为微溶的衍生物,例如作为微溶的盐。
在一特定的实施方案中,药物组合物可以在控释或缓释系统中递送。在一个具体实施方案中,可用泵来实现控释或缓释(参见Langer,Science,249:1527-1533(1990);Sefton,1987,CRC Crit.Ref.Biomed.Eng.14:10;Buschwald等人,1980,Surgery 88:507;Saudek等人,1989 N.Engl.J.Med.321:574)。另一个实施方案中,聚合物材料可以用于实现活性成分的控释或缓释(参见例如Medical Applications of Controlled Release,Langer and Wise(eds.),CRC Pres.,Boca Raton,Florida 1974);Controlled DrugBioavailability,Drug Product Design and Performance,Smolenand Ball(eds.),Wiley,New York(1984);Ranger and Peppas,1983,J.Macromol.Sci.Rev.Macrol.Chem.23:61;也参见Levy等人,1985 Science 228:190;During等人,1989,Ann.Neurol.25:351;Howard等人,1989,J.Neurosurg.71:105;美国专利第5,679,377号;美国专利第5,916,597号,美国专利第5,912,015号;美国专利第5,989,463号;美国专利第5,128,326号;PCT公开号WO99/12154;和PCT公开号WO 99/20253)。用于缓释制剂的聚合物的例子包括但并不限于聚(甲基丙烯酸2-羟基乙酯)、聚甲基丙烯酸甲酯、聚丙烯酸、聚(乙烯-共-乙酸乙烯酯)、聚甲基丙烯酸、聚乙交酯(PLG)、聚酐、聚(N-乙烯基吡咯烷酮)、聚乙烯醇、聚丙烯酰胺、聚乙二醇、聚丙交酯(PLA)、聚(丙交酯-共-乙交酯)(PLGA)和聚原酸酯。在一个优选的实施方案中,用在缓释制剂中的聚合物是惰性的、不含可滤除的杂质的、保存稳定的、无菌的和可生物降解的。另一个实例是,控释或缓释体系可以放在接近治疗靶点的地方,从而只需要全身剂量的一部分(参见例如Goods on,in Medical Applications ofControlled Release,supra,vol.2,pp.115-138(1984))。
作为本发明的特征,洛沙平和阿莫沙平给药的优选方法是通过吸入给药或肺部给药。肺部递药可以通过几种不同的方法实现,包括液体喷雾器、基于气雾剂的计量剂量吸入器(MDI′s)和干粉分配装置。用于这类给药的组合物通常是干粉或气雾剂。对于气雾剂给药来说,其是本发明优选的给药方法,组合物通常通过吸入器递送,一些类型的吸入器在下面描述。
除了活性成分,干粉包含载体、吸收促进剂和任选的其它成分。载体是例如单-、二-或多糖、糖醇或其它多元醇。合适的载体包括乳糖、葡萄糖、棉子糖、松三糖、乳糖醇、麦芽糖醇、海藻糖、蔗糖、甘露醇和淀粉。尤其优选乳糖,尤其是它的一水合物形式。还包括吸收促进剂,例如多肽、表面活性剂、烷基糖苷、脂肪酸的铵盐或磷脂。制剂成分通常必须具有良好的分散形式,也就是它们的质量中位数直径按照激光衍射装置或库尔特粒度仪的测量,通常应当小于大约5-10μm,优选大约1到大约5μm。可用本领域已知的方法,例如磨、微粉化或直接沉淀来生产需要的颗粒大小。
对于吸入给药来说,本发明化合物方便地以浓缩气雾剂的形式递送,正如2003年5月20日申请的美国专利申请系列第10/152,639号中论述的,其被全文引入作为参考。优选用于本发明的是气雾剂形式的洛沙平或阿莫沙平的吸入或肺部给药,优选具有大约0.01到大约3μm的总气体动力学中位数直径(MMAD)的气雾剂。这种气雾剂可从药物薄膜制备,其本身可用溶于适当溶剂的药物的溶液或药物本身的熔融物来制备。用这种薄膜(其中,膜优选具有大约0.05到大约20μm的厚度)生产洛沙平和阿莫沙平气雾剂的特别适合的装置公开在2003年8月4日申请的、标题为“薄膜药物递送物及使用方法”的待审的美国专利申请系列第10/633,877号中,和2003年8月4日申请的、标题为“快速加热药物递送物及使用方法”的系列第10/633,876号中,两篇都特此被全文引入作为参考。该气雾剂产品优选在足以提供气雾剂中的活性成分至少50%回收的汽化条件下使用,其中,所述气雾剂包含少于大约5%重量的化合物降解产物。
当阿莫沙平和洛沙平被用于治疗头痛发作,尤其是偏头痛时,优选阿莫沙平或洛沙平被快速递送,以至于最大血浆浓度优选在给药的30分钟内出现,更优选15分钟,最优选5分钟。这样快速的药物吸收可以通过以下途径包括静脉内递送或气雾剂吸入来实现,但气雾剂给药是优选途径。
更特别地,本发明为偏头痛治疗提供了洛沙平的递送方法,其中,最大血药浓度在给药30分钟内达到,优选在给药15分钟内达到。这可以导致洛沙平血液浓度的最大增长率为至少1ng/ml/分钟,在给药15分钟内洛沙平的血液浓度至少为5ng/ml。
对于使用阿莫沙平治疗偏头痛来说,本发明类似地提供了阿莫沙平的递送方法,其中阿莫沙平的最大血药浓度在给药30分钟内达到,优选在给药15分钟内达到。这可以导致阿莫沙平血液浓度的最大增长率为至少3ng/ml/分钟,在给药15分钟内阿莫沙平的血液浓度至少为10ng/ml。
这些药物浓度的快速到达优选通过从药物薄膜生产气雾剂来实现,最优选使用在上述两篇专利申请中公开的薄膜和快速加热装置。
本发明组合物可以与一种或多种其它治疗剂一起用于联合治疗,只要联合给药不导致洛沙平或阿莫沙平的疼痛减轻作用的抑制或产生不希望的联用效果。洛沙平或阿莫沙平及其它治疗剂可有加合作用或协同作用。优选的实例是,本发明组合物与其它治疗剂同时给药,它可以是含本发明洛沙平或阿莫沙平的相同组合物的一部分,或是不同组合物。另一个实例是,洛沙平或阿莫沙平在其它治疗剂给药之前或之后给药。参与慢性疼痛治疗的联合治疗的实例是,联合治疗包括交替给予含洛沙平或阿莫沙平的组合物和包含其它治疗剂的组合物,例如以减小与特定药物有关的毒性。两者之一的给药期间可以是例如一个月、三个月、六个月、一年或更长时间。某些实例是,当本发明化合物与潜在地产生不利副作用的包括但并不限于毒性的其它治疗剂同时给药时,治疗剂可以有利地以低于产生副作用的阈值的剂量给药。
例如,一定量或一定剂量的本发明的洛沙平或阿莫沙平可以在剂型中与其它镇痛药联合,例如阿片类、非甾体抗炎药(NSAIDs)等,包括氢吗啡酮、可待因、吗啡、尼可吗啡、hydroxycodone、芬太尼、阿司匹林、布洛芬、双氯芬酸、萘普生、benoxaporfen、氟比洛芬、非诺洛芬、酮洛芬、吲哚洛芬、carporfen、奥沙普秦、舒洛芬、噻洛芬酸、吲哚美辛、舒林酸、托美丁、佐美酸、阿西美辛、fentiaza、甲芬那酸、甲氯芬那酸、氟芬那酸、尼氟酸、托芬那酸、吡罗昔康、伊索昔康或其可药用盐、前药或其混合物。可包含在本发明剂型中的其它合适的镇痛药包括甾体抗炎药,例如糖皮质激素、地塞米松(DECADRONTM)、可的松、氢化可的松、强的松、泼尼松龙、曲安西龙;类花生酸类物质,例如前列腺素类、血栓素类和白细胞三烯类;水杨酸衍生物,包括阿司匹林、水杨酸钠、三水杨酸胆碱镁、双水杨酯、二氟尼柳、水杨酰水杨酸、柳氮磺吡啶和奥沙拉秦;对氨基苯酚衍生物包括对乙酰氨基酚和非那西丁;吲哚和茚乙酸,包括吲哚美辛、舒林酸和依托度酸;环氧合酶2特异性抑制剂,包括塞来考昔、罗非考昔、伐地考昔、eterocoxib和帕瑞考昔;杂芳基乙酸,包括托美丁和酮咯酸;anthtanilic acids,包括mefanamic acid和甲氯芬那酸;烯醇酸类,包括昔康类(例如吡罗昔康或替诺昔康);和吡唑烷二酮类(例如保泰松);和alkanones,包括萘丁美酮。
洛沙平或阿莫沙平也可联合其它抗偏头痛剂例如阿吡必利、双氢麦角胺、多拉司琼、麦角柯宁碱、麦角异柯宁碱、麦角隐亭、麦角碱、麦角胺、二甲替嗪、麦角乙脲、洛美利嗪、美西麦角、奥昔托隆、苯噻啶、舒马普坦、利扎曲普坦、那拉曲坦、依来曲普坦、夫罗曲普坦、多尼普曲坦、佐米曲坦及其混合物制成药物剂型。
洛沙平或阿莫沙平也可联合抗抑郁剂制成药物剂型。合适的抗抑郁剂包括但并不限于卡罗沙酮、西酞普兰、二甲沙生、芬咖明、吲达品、盐酸茚洛秦、奈福泮、诺米芬辛、奥昔哌汀、帕罗西汀、舍曲林、胺苯硫卓酮、曲唑酮、异丙氯肼、异丙烟肼、异卡波肼、奥他莫辛、苯乙肼、可替宁、咯利普兰、马普替林、美曲吲哚、米安色林、米氮平、阿地唑仑、阿米替林、氧阿米替林、布替林、氯米帕明、地美替林、地昔帕明、二苯西平、二甲他林、多塞平、三氟丙嗪、丙米嗪、丙米嗪N-氧化物、伊普吲哚、洛非帕明、美利曲辛、美他帕明、去甲替林、肟替林、奥匹哌醇、苯噻啶、丙吡西平、普罗替林、奎纽帕明、噻奈普汀、曲米帕明、阿屈非尼、贝那替秦、丁氨苯丙酮、布他西丁、地奥沙屈、度洛西汀、依托哌酮、非巴氨酯、非莫西汀、芬戊二醇、氟西汀、氟伏沙明、血卟啉、金丝桃蒽酮、左芬氟拉明、米那普令、吗氯贝胺、奈法唑酮、奥沙氟生、吡贝拉林、普罗林坦、吡琥胺酯、利坦色林、罗克吲哚、氯化铷、舒必利、坦度螺酮、托扎啉酮、托芬那辛、托洛沙酮、反苯环丙胺、L-色氨酸、文拉法辛、维洛沙秦和齐美定。
类似地,洛沙平或阿莫沙平可与抗癫痫药例如丙戊酸盐、苯妥英、苯巴比妥、扑米酮、卡马西平、乙琥胺或氯硝西泮联用。
实施例
下列实施例进一步阐述了此处描述的发明,而决不试图限制发明范围。
具体实施方式
实施例1
小鼠扭曲试验
体重23-28g的雄性小鼠用于本试验。用乙酸(0.5%i.p.)给小鼠注射。这种处理导致对照动物可辨认的扭曲反应。从注射乙酸后5分钟开始,计算10分钟内的扭曲次数。每组研究十只小鼠。试验双盲进行。评价5个剂量的洛沙平和阿莫沙平(分散在0.2%羟丙甲基纤维素中,然后溶于生理盐水),给予乙酸前30分钟腹膜内注射,并与赋形剂对照组(0.2%羟丙甲基纤维素的生理盐水溶液)比较。洛沙平的剂量等级是0.125、0.25、0.5、1和2mg/kg。阿莫沙平的剂量等级是1、2、4、8和16mg/kg。在相同实验条件下给药的吗啡(8mg/kg i.p.)被用作参照物。用Mann Whitney U检验比较治疗组和赋形剂对照组,分析数据。
结果显示在表1中:
表1
用阿莫沙平、洛沙平和吗啡预处理后乙酸扭动的减少。
数据表示成对照赋形剂预处理的百分数。
Mann-Whitney U检验:NS=不显著;*=p<0.05;**=p<0.01;***=p<0.001
如表1中所示,阿莫沙平剂量依赖性地减少乙酸诱导的扭动次数,从2mg/kg开始有显著性差异。从4mg/kg开始观察到了清楚的效果。洛沙平剂量依赖性地减少乙酸诱导的扭动次数,从0.125mg/kg开始有显著性差异。从0.25mg/kg开始观察到了明显效果。从2mg/kg阿莫沙平和0.25mg/kg洛沙平开始观察到了镇静作用。在每组实验中,吗啡都显著地拮抗乙酸诱导的扭动。
实施例2
洛沙平吸入气雾剂对小猎犬的急性和5日重复剂量毒性研究
本研究的目的是在对狗的5日重复剂量研究中调查洛沙平的两个临床有关剂量的个体最大耐受剂量和潜在毒性。
本研究是在CTBR,87 Senneville Road,Senneville,Quebec,Canada,H9X 3R3,应用CTBR′s标准操作方法进行的。
试验品是通过口咽吸入递送的洛沙平气雾剂。
治疗开始时所用的动物是从Covance Research Product,Route 2,Box 113,Cumberland,VA 23040购买的、大约7-10月龄、6-12kg的小猎犬。动物在装有条形地板和自动水阀的不锈钢笼中单独饲养。每个笼子都清楚地贴上了用不同色彩作标记的笼子卡片的标签,标明了计划、组别、动物和纹身号以及性别。每只动物都用一只耳廓腹面上的永久纹身号和/或字母唯一识别。
动物房间环境和光周期条件如下:
温度 | 20±3℃ |
湿度 | 50±20% |
光周期 | 12小时明亮,12小时黑暗(除了指定操作期间以外) |
所有动物都可接近标准鉴定的丸状商购狗食(400g-PMICertified Dog Chow 5007:PMI Nutrition International Inc.),除了指定操作期间以外。
控制食物中最大许可的污染物(例如重金属、黄曲霉素、有机磷酸酯、氯代烃类、PCBs)浓度。
已经过软化、反渗透纯化并暴露于紫外线的地方自来水可自由得到(除了指定操作期间以外)。
在接收到动物和开始处理之间允许有大约3周的驯化周期,以使动物习惯于实验室环境。
处理开始前,所有动物都称重并用随机方法分配到处理组。用体重作为参数,通过分层来随机。雌雄分别随机。检查最终的动物分配,确保同窝出生的仔犬均一地分布在所有组中。
将动物分配成下列各组:重复剂量洛沙平2mg/kg(2雄2雌),重复剂量洛沙平0.2mg/kg(2雄2雌),赋形剂对照重复剂量(2雄2雌),和间隔至少48小时的洛沙平单一加强剂量(1雄1雌)。
使用装有入口管和出口管的口咽面罩,用试验气雾剂处理动物。在处理期间,将动物放在制约悬带内。
使用允许狗吸入试验物质的面罩。这个面罩由塑料圆柱体组成,按如下方法装在狗的口鼻上:鼻子在圆柱体里面,动物通过短管用嘴呼吸。将箔在溶于有机溶剂的洛沙平的溶液中进行浸渍涂布,将由此已经在不锈钢箔上形成了大约4微米厚的洛沙平膜加热到大约400℃,蒸发洛沙平,产生试验品。将由蒸发的洛沙平凝结形成的最终气雾剂经由预干燥的压缩气体导入混和舱中。在位于排气管路的闸阀维持的微正压下操作混和舱。使用真空泵以需要的流速排出吸入舱中的废气,并在空气排出房间之前将被污染的空气(过量气雾剂和呼出的空气)通过由5μm的粗糙过滤器组成的净化系统过滤。经由传输管道将最终空气输送到狗面罩中。
将赋形剂对照组暴露于通过了药物加热装置的预干燥的压缩空气中,装置装有洁净的不锈钢箔而不是洛沙平涂布箔。除了不含药物以外,给药也用于与2mg/kg重复剂量组相配,使用通过运行的并从而加热的装置的空气,狗只通过狗面罩呼吸,狗被相同的方式制约和处理。
为了确保剂量准确,在每天开始处理之前,进行试验品气雾剂的大气表征。用在典型的动物暴露面罩处收集的露面玻璃纤维过滤器样品,按重量测定需要建立各个靶气雾剂浓度的暴露系统的操作条件。
还测定0.2mg/kg和2mg/kg剂量水平的洛沙平舱大气浓度的均一性。这包括从位于混和舱周围的2个等距间隔的狗呼吸舱门处收集双份过滤样品用于重量分析。也从对照舱门收集其它样品来评价舱内总的和舱门内的试验品分布的变化。这项分析获得的结果证明了均一的气雾剂分布。
用级联冲击器进行每个洛沙平剂量的气雾剂颗粒大小分布的分析。方法由分成一系列大小范围,接着进行重量分析组成。使用基于Andersen Operating Manual TR#76-900016的计算机程序,从重量分析数据计算质量中位数直径及其几何标准偏差(MMAD±GSD)。研究期间测得的典型质量中位数直径和GSD是1.4μm±2.2。
在每个暴露日子里,从动物呼吸区的样品舱门,使用重量分析法至少测量一次确切的气雾剂面罩输出浓度。
如下测量每个处理浓度所达到的活性成分剂量(mg/kg/天):
在第一次药物处理之前,使用Buxco Electronics LS-20系统测量每只动物两次。
从研究逐渐升高的剂量部分的特定剂量日子抽取的活性成分实现的剂量示例性计算如下:
平均舱气雾剂浓度:0.489mg/L
MMAD±GSD:1.1μm±2.2。基于Witschi & Nettesheim,Mechanisms in Respiratory Toxicology,Vol.1:54-56,CRC Press,Inc.1982,上述MMAD和GSD导致0.38的沉积分数(D)。
平均BW:8.3kg
平均预实验RMV:7.86L/min(假定研究期间不变)
暴露时间:15分钟
应用上表中的公式,上述数据得到2.6mg/kg的实现剂量。
使用上述方法递送药物气雾剂,用洛沙平气雾剂处理狗,计算递送剂量。刚开始,1雄1雌接受洛沙平1mg/kg/剂量,没有观察到动物行为的改变。几天以后,这些相同的动物接受洛沙平2.6mg/kg,这导致虚弱、震颤和活动减少。
接着,2只雄狗和2只雌狗如上接受赋形剂对照5天。它们没有显示行为改变。另外,2只雄狗和2只雌狗接受洛沙平0.2mg/kg(每天)5天。它们没有显示行为改变。最后,2只雄狗和2只雌狗接受洛沙平2mg/kg(每天)5天。它们显示出虚弱、震颤和活动减少,但没有呼吸副作用例如咳嗽。特别地,没有发现支气管收缩例如喘息、呼气相延迟或咳嗽的迹象。所有动物的食物消耗大致正常。
处理阶段完成后,静脉内注射戊巴比妥钠麻醉,接着切开腋动脉或股动脉放血,对动物进行验尸。将动物从动物室运送到验尸区之前,肌内注射给予镇静的盐酸氯胺酮注射液U.S.P.和甲苯噻嗪。为了避免自溶改变,立即对所有实施了安乐死的动物进行畜体的完全粗略的病理学检查。在预定验尸之前,所有动物通宵停止供给食物。验尸期间没有检查到任何动物与处理有关的发现。进行任何粗略损伤的组织病理学检查。也没有观察到与处理有关的结果。另外,进行喉、气管、主支气管、肺包括支气管的组织病理学检查。没有观察到与处理有关的异常。
在研究的重复剂量(5天)部分的第一天,在给药前、开始给药后2分钟、给药后即刻、给药后20分钟、1、3、9和24小时收集血浆样品进行毒物代谢动力学分析。在-80℃下储存样品直至进行洛沙平血浆浓度分析。可以使用本领域熟知的分析方法例如LC/MS、LC/MS/MS和/或GC/MS检测洛沙平血浆浓度。预示典型的洛沙平毒物代谢动力学数据提供在图1和2中。在这些数据中注意进行气雾剂洛沙平给药后,洛沙平血浆浓度增加得非常快,药物吸入后2分钟内达到了血浆峰浓度。发现2mg/kg剂量水平时,经过给药的第一个2分钟,洛沙平血浆浓度的增长率平均为至少70ng/mL/分钟,2mg/kg剂量水平时,经过给药的第一个10分钟,为20ng/mL/分钟。发现0.2mg/kg剂量水平时,经过给药的第一个2分钟,洛沙平血浆浓度的增长率平均为至少7ng/mL/分钟,0.2mg/kg剂量水平时,经过给药的第一个10分钟,为2ng/mL/分钟。在两个剂量水平下,10分钟、5分钟、甚至2分钟内获得了大约至少0.5ng/mL、1ng/mL、2ng/mL、4ng/mL、8ng/mL或甚至15ng/mL的治疗血浆浓度。
预示实施例
实施例3
洛沙平浓缩气雾剂的I期临床试验
如2003年8月4日申请的、标题为“快速加热药物递送物及使用方法”的美国专利申请系列第10/633,876号所公开的浓缩气雾剂发生手持装置被涂布上洛沙平,通过患者吸气启动装置后经过小于1秒的期间,释放0、2.5mg、5mg或10mg(取决于涂布厚度)的洛沙平浓缩气雾剂。
招募一般在18到45岁的、没有患严重精神病、神经病、肺病、肾病或心血管疾病的普通志愿者来参与本项研究,向他们解释洛沙平吸入的潜在危险,并寻求他们的知情同意。那些同意的参与本项研究,放置静脉内导管。
给予志愿者手持装置。在接受装置之前,他们可能接受或可能没有接受训练以适当的呼吸技巧来使用装置。最低限度地,每名志愿者要被教导完全呼气,然后将装置放在他的或她的嘴唇内,并进行长的、深吸气,在呼气之前保持几秒钟。然后志愿者使用装置,接受规定量的洛沙平浓缩气雾剂。志愿者和进行研究的医务人员对于药物剂量或药物是否被安慰剂所代替(例如装有0mg洛沙平的装置)都是不知道的。
给药后大约0.3、1、3、10、30、60、120、240、360、500、750和1000分钟采集静脉血样。用文献中描述的对洛沙平建立的方法测定血药浓度。这些分析显示Tmax小于10分钟,Tmax通常在3分钟样品或1分钟样品中出现。浓缩气雾剂递送的生物利用度大于35%,通常大于55%。
下表提供了不同剂量时的说明性的预期Cmax值:
剂量 | Cmax通常大于 | 最典型的Cmax大于 |
2.5mg | 2.5ng/mL | 15ng/mL |
5mg | 5ng/mL | 30ng/mL |
10mg | 10ng/mL | 60ng/mL |
20mg | 20ng/mL | 120ng/mL |
实施例4
治疗急性偏头痛发作的洛沙平II期临床试验
研究方法学是双盲、随机、安慰剂对照、剂量范围试验。招募18到65岁(包括)的健康男性和女性患者参与本项研究,他们自我报告具有中度到重度偏头痛(有或没有先兆的偏头痛),在过去3个月内每月平均发作1-6次。符合入选标准的那些患者参与并随机接受下列处理之一:安慰剂,洛沙平快速递药系统~1.25mg,洛沙平快速递药系统~2.5mg,洛沙平快速递药系统~5mg,洛沙平快速递药系统~10mg。如果在I期临床试验中发现是安全的,也可试验较高的洛沙平剂量。洛沙平快速递药系统是将洛沙平递送给偏头痛患者使得最大血药浓度在1小时、30分钟、15分钟、10分钟、5分钟甚或2分钟或更短时间内获得的手段。至于上述I期临床试验的浓缩气雾剂递药系统就是一个这样的系统。其它快速递药系统包括静脉内输液或注射液的各个时期。
被随机化的患者接受治疗前即刻,患者按4分标准评定他们的头痛和恶心的严重度等级(0-没有,1-轻度,2-中度,3-重度),按2分标准评定畏光和声音恐怖等级(光使你的头痛更糟糕吗?0-不是,1-是的;噪音使你的头痛更糟糕吗?0-不是,1-是的)。择一地,可以使用11分直观模拟标准(0-没有到10-最严重)或其它适当的标准。处理后15分钟和30分钟,以及处理后1、2、4、8、12和24小时,让患者重复这些等级评定。处理后120分钟和24小时,再让患者对治疗效果进行整体评价(1-很差到5-很好)。如果有的话,也要记录伴随药物。
接受5mg和10mg洛沙平的组在1小时内显示了很强的药物疗效。特别地,经治疗的患者在1小时、甚至30分钟、有时甚至15分钟时,头痛的严重性比治疗前显著降低了。1小时时,比较安慰剂和5mg或10mg的头痛缓解程度,洛沙平治疗的患者显示了显著的优势,药物相对安慰剂在较低的偏头痛得分、较低的恶心得分、较少出现畏光和声音恐怖、相对基线得分头痛得分更大的降低、更大百分数的只有轻度头痛或不头痛的患者、更大百分数的不头痛的患者方面,被统计学显著(p<0.05的水平)的优势所证明。这个优势持续到2小时、4小时、8小时、甚至24小时,除非给经安慰剂处理的患者提供救援药物。在1.25mg或2.5剂量水平的适当大的样本数中也看到了类似的效果,尽管有些时候,那种剂量水平的适当大的患者样本数难以获得(因为效果有时不强,需要更多的患者)。而且,在1.25mg或2.5mg的较低剂量水平,药物有时需要更长的持续时间(例如1小时而不是30分钟)才能有效。
实施例5
临床应用洛沙平治疗急性偏头痛发作
一名通常身体很好的35岁妇女指出当她在家时,位于她的头右侧的中度头痛发作了大约10分钟。接下来的10分钟,疼痛变得更严重了,具有伴随搏动的特征。妇女意识到这是偏头痛,也知道她的这种头痛如果不治疗,会持续至少一整天,伴随头痛还同时出现恶心,同时疼痛很严重以至于睡眠困难或不可能。妇女关闭了她的寝室的灯,以避免由光亮进入她的眼睛引起的疼痛,并关闭了收音机,因为来自收音机的噪音加重了她的头痛。她用一杯水口服了25mg洛沙平。经过又一个15分钟,头痛开始更严重了,妇女的胃轻微不适。然而,经过接下来的1小时,头痛缓慢消失了,妇女变得愈加疲劳。她的胃不再困扰她。她稍微打了个盹,醒来后没有任何头痛迹象。光和声不再令人烦恼。她吃了正常的食物而没有胃部不适。经过了72小时,头痛没有再次发作,不再需要更多的药物。
可以理解的是,此处描述的实施例和实例仅用于阐述目的,在其启发下的各种修正或改变会被提供给本领域技术人员,被包括在本申请精神和范围之内和附加权利要求的范围之内。
此处引用的所有出版物、专利和专利申请特此被全文引入作为参考,用于所有目的。
Claims (22)
1.有效量的选自洛沙平和洛沙平的可药用盐的化合物制备治疗患者头痛的药物的用途,所述患者被给药包含所述化合物的药物组合物。
2.根据权利要求1的用途,其中,所述有效量是足以减轻所述患者存在的头痛的量。
3.根据权利要求1的用途,其中所述药物组合物是全身给药。
4.根据权利要求1-3任一项的用途,其中,所述头痛是偏头痛。
5.根据权利要求1-3任一项的用途,其中,所述头痛是丛集性头痛。
6.根据权利要求1-3任一项的用途,其中,所述头痛是紧张性头痛。
7.根据权利要求1-3任一项的用途,其中,所述药物组合物通过吸入给药。
8.根据权利要求1-3任一项的用途,其中,所述患者是人,所述头痛是偏头痛,并且所述药物组合物通过吸入给药。
9.根据权利要求1-3任一项的用途,其中所述药物组合物为气雾剂形式。
10.根据权利要求1-3任一项的用途,其中所述药物组合物为浓缩气雾剂的形式,其中所述浓缩气雾剂是通过将物质蒸发,然后将该物质缩聚成气溶胶而形成。
11.根据权利要求9的用途,其中,所述气雾剂具有0.01到3μm的总气体动力学中位数直径。
12.根据权利要求1-3任一项的用途,其中给予0.3到20mg洛沙平,或给予一定量的洛沙平的盐,这个量能给患者产生相当于给予0.3到20mg洛沙平时洛沙平的血药浓度。
13.根据权利要求1-3任一项的用途,其中,给予1到10mg洛沙平,或给予一定量的洛沙平的盐,这个量能给患者产生相当于给予1到10mg洛沙平时洛沙平的血药浓度。
14.根据权利要求1-3任一项的用途,其中,将洛沙平或其盐对患者给药,以在所述给药的30分钟内产生洛沙平的最大血药浓度。
15.根据权利要求1-3任一项的用途,其中,将洛沙平或其盐对患者给药,以在所述给药的15分钟内产生洛沙平的最大血药浓度。
16.根据权利要求1-3任一项的用途,其中,将洛沙平或其盐对患者给药,以导致洛沙平血液浓度的最大增长率为至少1ng/ml/分钟。
17.根据权利要求1-3任一项的用途,其中,将洛沙平或其盐对患者给药,以在所述给药的15分钟内产生至少5ng/ml的洛沙平血药浓度。
18.根据权利要求1的用途,其中,使用快速加热药物递送物或薄膜药物递送物通过吸入对所述药物组合物给药,所述快速加热指的是将所述药物在50-500ms的时间内加热到至少200℃、250℃、300℃或350℃。
19.根据权利要求1的用途,其中,通过吸入递送装置给药所述药物组合物,所述化合物被蒸发和凝结以提供气雾剂形式的所述化合物的至少50%回收,并且其中,所述气雾剂包含少于5%重量的药物组合物降解产物。
20.根据权利要求19的用途,其中,所述化合物作为具有0.5到20μm膜厚度的薄膜被覆盖在递送装置中的基层上。
21.根据权利要求1的用途,其中,所述药物组合物以总气体动力学中位数直径(MMAD)0.01到3μm的气雾剂的形式给药。
22.根据权利要求1的用途,其中,所述药物组合物通过快速加热药物递送物给药,所述化合物在足以提供所述化合物的至少50%回收,并且包含少于10%重量的化合物降解产物的气雾剂的条件下从混合的化合物组合物膜中蒸发。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42940502P | 2002-11-26 | 2002-11-26 | |
US60/429,405 | 2002-11-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003801041511A Division CN1717237A (zh) | 2002-11-26 | 2003-11-20 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101371843A CN101371843A (zh) | 2009-02-25 |
CN101371843B true CN101371843B (zh) | 2012-09-26 |
Family
ID=32393557
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101336457A Expired - Lifetime CN101371843B (zh) | 2002-11-26 | 2003-11-20 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
CNA2003801041511A Pending CN1717237A (zh) | 2002-11-26 | 2003-11-20 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003801041511A Pending CN1717237A (zh) | 2002-11-26 | 2003-11-20 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8288372B2 (zh) |
EP (1) | EP1567164B1 (zh) |
JP (1) | JP2006514934A (zh) |
CN (2) | CN101371843B (zh) |
AT (1) | ATE420647T1 (zh) |
AU (1) | AU2003294470B2 (zh) |
CA (1) | CA2507159A1 (zh) |
DE (1) | DE60325888D1 (zh) |
DK (1) | DK1567164T3 (zh) |
ES (1) | ES2321292T3 (zh) |
HK (1) | HK1125845A1 (zh) |
MX (1) | MXPA05005611A (zh) |
NZ (1) | NZ540207A (zh) |
PT (1) | PT1567164E (zh) |
WO (1) | WO2004047844A1 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
JP2005503425A (ja) * | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
NZ529417A (en) * | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals Inc | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
WO2003057188A1 (en) * | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CA2507158A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
ES2370395T3 (es) | 2003-05-21 | 2011-12-15 | Alexza Pharmaceuticals, Inc. | Utilización de una capa de combustible sólido, procedimiento para fabricarla y unidad de calefacción correspondiente. |
CA2534566A1 (en) * | 2003-08-04 | 2005-02-24 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing and use |
EP1670479A1 (en) * | 2003-09-04 | 2006-06-21 | H. Lundbeck A/S | The combination of a serotonin reuptake inhibitor and amoxapine |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
JPWO2006095788A1 (ja) * | 2005-03-09 | 2008-08-14 | 小野薬品工業株式会社 | 粒子およびその粒子を含有する製剤 |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
US20070259829A1 (en) * | 2006-03-24 | 2007-11-08 | Maen Abdelrahim | Uses of diphenyl/diphenylamine carboxylic acids |
WO2008080170A1 (en) * | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
JP5570996B2 (ja) | 2007-12-14 | 2014-08-13 | エアロデザインズ インコーポレイテッド | エアロゾル化可能な食料品の送達 |
US20100065052A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
US9345689B2 (en) | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
CN111249584B (zh) | 2013-07-11 | 2022-04-26 | 艾利斯达医药品公司 | 与间水杨酸形成的烟碱盐 |
KR102217768B1 (ko) | 2015-03-11 | 2021-02-19 | 알렉스자 파마스티칼즈, 인크. | 열 에어로졸 응축 공정을 위한 에어웨이에서 대전방지 소재의 용도 |
US20170216220A1 (en) * | 2016-02-03 | 2017-08-03 | Intelgenx Corp. | Loxapine film oral dosage form |
SI3551189T1 (sl) | 2016-12-09 | 2024-03-29 | Alexza Pharmaceuticals, Inc. | Uporaba alprazolama pri terapiji za epilepsijo |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020156052A1 (en) * | 2000-11-17 | 2002-10-24 | Dehaven Robert | Delta agonist analgesics |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
NL289785A (zh) | 1962-11-29 | |||
GB1063512A (en) * | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
AT258912B (de) | 1964-05-27 | 1967-12-27 | Wander Ag Dr A | Verfahren zur Herstellung neuer 11-basisch substituierter Dibenz [b,f] [1,4]oxazepine |
USRE30285E (en) * | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
US3949743A (en) * | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
US4141369A (en) * | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
US4183912A (en) * | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
DE3116951C2 (de) | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Vorrichtung zur Beimischung flüssiger Narkosemittel in das dem Patienten zuzuführende Atemgas |
DE3224849A1 (de) * | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Dampfinhaliergeraet |
US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
IT1173445B (it) | 1984-03-16 | 1987-06-24 | Guidotti & C Spa Labor | Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono |
US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
WO1986006959A1 (en) * | 1985-05-22 | 1986-12-04 | Liposome Technology, Inc. | Liposome inhalation method and system |
US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4734560A (en) * | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
US4819665A (en) * | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US4924883A (en) * | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
US4906417A (en) * | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
US5345951A (en) | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
EP0358114A3 (en) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Aerosol delivery articles utilizing electrical energy |
US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
US5511726A (en) * | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US4917119A (en) * | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
DE3908161A1 (de) | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Rauchbarer artikel |
US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5224498A (en) | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
US5144962A (en) | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
GB2239807A (en) | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
US5099861A (en) * | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
ES2073685T5 (es) * | 1990-08-02 | 2002-03-01 | Datex Ohmeda Inc | Vaporizador de anestesico. |
ATE179605T1 (de) * | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US5318033A (en) | 1992-04-17 | 1994-06-07 | Hewlett-Packard Company | Method and apparatus for increasing the frame rate and resolution of a phased array imaging system |
US5626871A (en) | 1992-06-12 | 1997-05-06 | Teijin Limited | Preparation for intratracheobronchial administration |
US5284133A (en) * | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
US5915378A (en) * | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5666977A (en) | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
EP0706352B1 (en) * | 1993-06-29 | 2002-03-20 | Ponwell Enterprises Limited | Dispenser |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
DE4328243C1 (de) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Rauch- oder Inhalationsvorrichtung |
US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
FI98270C (fi) * | 1993-11-29 | 1997-05-26 | Instrumentarium Oy | Menetelmä ja sovitelma anesteetin höyrystämisen yhteydessä |
US6102036A (en) | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
US5522385A (en) * | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5758637A (en) * | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5649554A (en) | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
US5564442A (en) | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
SE9504580L (sv) | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Förfarande vid förgasning av en narkosvätska och en förgasare |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5699789A (en) | 1996-03-11 | 1997-12-23 | Hendricks; Mark R. | Dry powder inhaler |
CN1146421C (zh) | 1996-03-25 | 2004-04-21 | 伊莱利利公司 | 治疗疼痛的组合物以及药物在制备所述组合物中的应用 |
WO1997035582A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating migraine pain |
CZ298198A3 (cs) | 1996-03-25 | 1999-06-16 | Eli Lilly And Company | Farmaceutický přípravek |
EP0906104A4 (en) | 1996-03-25 | 2003-12-10 | Lilly Co Eli | PAIN TREATMENT PROCESS |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5743251A (en) * | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6694975B2 (en) | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
CA2280099C (en) | 1997-02-05 | 2005-12-27 | Jago Pharma Ag | Medical aerosol formulations |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
DE19727297C2 (de) * | 1997-06-27 | 2003-11-13 | Bosch Gmbh Robert | Verfahren zum Betreiben einer Brennkraftmaschine insbesondere eines Kraftfahrzeugs |
KR100289448B1 (ko) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | 향미발생장치 |
US6090212A (en) | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US5900249A (en) * | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
WO1999044594A1 (fr) | 1998-03-05 | 1999-09-10 | Nippon Shinyaku Co., Ltd. | Emulsions huileuses destinees a etre administrees par inhalation |
JP2002515503A (ja) * | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
US6095153A (en) | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6234167B1 (en) * | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6255334B1 (en) | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
US6591839B2 (en) | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
NZ517575A (en) * | 1999-09-30 | 2004-04-30 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
AU2001234005B2 (en) | 2000-02-28 | 2006-01-19 | Pharmakodex Limited | Improvements in or relating to the delivery of oral drugs |
US6632047B2 (en) | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
MY136453A (en) * | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
EP1292314A2 (en) | 2000-05-23 | 2003-03-19 | The Trustees of Columbia University in the City of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans |
NZ505417A (en) * | 2000-06-23 | 2003-05-30 | Papich Ltd R | Hydraulic resistance brake actuated by inertia for vehicle axles |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020117175A1 (en) | 2000-10-27 | 2002-08-29 | Kottayil S. George | Thermal vaporizing device for drug delivery |
AUPR283801A0 (en) * | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
JP2005511477A (ja) | 2001-03-19 | 2005-04-28 | プラエシス ファーマシューティカルズ インコーポレーテッド | 持続放出のための医薬調合物 |
US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
US20030138508A1 (en) | 2001-12-18 | 2003-07-24 | Novack Gary D. | Method for administering an analgesic |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7645442B2 (en) * | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
NZ529417A (en) | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals Inc | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
WO2002094242A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US20030032638A1 (en) * | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
US20070122353A1 (en) * | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7585493B2 (en) * | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030051728A1 (en) * | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
PT1397145E (pt) * | 2001-06-19 | 2006-10-31 | Norbert Muller | Utilizacao de inibidores da cox-2 para o tratamento de esquizofrenia ou de disturbios de tiques |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1455875A2 (en) | 2001-11-21 | 2004-09-15 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
US6701922B2 (en) * | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6772756B2 (en) | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US7263214B2 (en) | 2002-05-15 | 2007-08-28 | Ge Medical Systems Global Technology Company Llc | Computer aided diagnosis from multiple energy images |
US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
CN1700934B (zh) * | 2002-09-06 | 2011-08-03 | 菲利普莫里斯美国公司 | 液体气溶胶制剂和用于制备气溶胶的气溶胶产生装置及方法 |
US6715416B1 (en) * | 2002-11-06 | 2004-04-06 | Mgs Mfg. Group, Inc. | Pod loader for transfer pad printing system |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CA2507158A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) * | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
ES2370395T3 (es) | 2003-05-21 | 2011-12-15 | Alexza Pharmaceuticals, Inc. | Utilización de una capa de combustible sólido, procedimiento para fabricarla y unidad de calefacción correspondiente. |
CA2534566A1 (en) * | 2003-08-04 | 2005-02-24 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing and use |
WO2005014090A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Pharmaceuticals, Inc. | Methods of determining film thicknesses for an aerosol delivery article |
CA2551127A1 (en) | 2003-12-15 | 2005-07-07 | Alexza Pharmaceuticals, Inc. | Treatment of breakthrough pain by drug aerosol inhalation |
US20050131739A1 (en) | 2003-12-16 | 2005-06-16 | Alexza Molecular Delivery Corporation | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real time |
US7402777B2 (en) * | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
CA2576961A1 (en) * | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
WO2006044421A2 (en) | 2004-10-12 | 2006-04-27 | Alexza Pharmaceuticals, Inc. | Cardiac safe, rapid medication delivery |
-
2003
- 2003-11-20 CN CN2008101336457A patent/CN101371843B/zh not_active Expired - Lifetime
- 2003-11-20 NZ NZ540207A patent/NZ540207A/en unknown
- 2003-11-20 US US10/719,540 patent/US8288372B2/en active Active
- 2003-11-20 DK DK03789955T patent/DK1567164T3/da active
- 2003-11-20 WO PCT/US2003/037415 patent/WO2004047844A1/en active Application Filing
- 2003-11-20 EP EP03789955A patent/EP1567164B1/en not_active Expired - Lifetime
- 2003-11-20 CA CA002507159A patent/CA2507159A1/en not_active Abandoned
- 2003-11-20 ES ES03789955T patent/ES2321292T3/es not_active Expired - Lifetime
- 2003-11-20 MX MXPA05005611A patent/MXPA05005611A/es active IP Right Grant
- 2003-11-20 PT PT03789955T patent/PT1567164E/pt unknown
- 2003-11-20 JP JP2004555617A patent/JP2006514934A/ja not_active Ceased
- 2003-11-20 AU AU2003294470A patent/AU2003294470B2/en not_active Ceased
- 2003-11-20 DE DE60325888T patent/DE60325888D1/de not_active Expired - Lifetime
- 2003-11-20 CN CNA2003801041511A patent/CN1717237A/zh active Pending
- 2003-11-20 AT AT03789955T patent/ATE420647T1/de active
-
2009
- 2009-05-15 HK HK09104445.4A patent/HK1125845A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020156052A1 (en) * | 2000-11-17 | 2002-10-24 | Dehaven Robert | Delta agonist analgesics |
Also Published As
Publication number | Publication date |
---|---|
EP1567164A1 (en) | 2005-08-31 |
DE60325888D1 (de) | 2009-03-05 |
ES2321292T3 (es) | 2009-06-04 |
AU2003294470A1 (en) | 2004-06-18 |
WO2004047844A1 (en) | 2004-06-10 |
WO2004047844A8 (en) | 2007-01-25 |
NZ540207A (en) | 2008-06-30 |
HK1125845A1 (en) | 2009-08-21 |
PT1567164E (pt) | 2009-03-31 |
EP1567164B1 (en) | 2009-01-14 |
CN1717237A (zh) | 2006-01-04 |
ATE420647T1 (de) | 2009-01-15 |
MXPA05005611A (es) | 2005-07-27 |
CA2507159A1 (en) | 2004-06-10 |
JP2006514934A (ja) | 2006-05-18 |
CN101371843A (zh) | 2009-02-25 |
DK1567164T3 (da) | 2009-05-18 |
US20040102434A1 (en) | 2004-05-27 |
US8288372B2 (en) | 2012-10-16 |
AU2003294470B2 (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101371843B (zh) | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 | |
JP5411504B2 (ja) | 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用 | |
JP2022523700A (ja) | 心理性、認知性、行動性、および/または気分性の障害を処置するための方法、ならびに5ht受容体アゴニストを含む組成物 | |
TW200824693A (en) | Pharmaceutical compositions of clonazepam and methods of use thereof | |
CN103502224A (zh) | 氟马西尼络合物、包含该络合物的组合物及其用途 | |
CN101370488A (zh) | 增加胰岛素敏感性的组合物和方法 | |
MX2014006961A (es) | Composiciones de dexmedetomidina intranasal y sus metodos de uso. | |
JP5208473B2 (ja) | アゼラスチンと抗コリン薬を含有する医薬組成物 | |
Carlson et al. | Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus | |
JP2012526854A (ja) | デクスメデトミジンの舌下組成物およびその使用方法 | |
CN105848650A (zh) | 促进吸烟停止 | |
JP2017534613A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
US20200223838A1 (en) | Methods of use of phenoxypropylamine compounds to treat depression | |
Jenkins et al. | Pharmacokinetics: drug absorption, distribution and elimination | |
EP2029139B1 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
JP2011506516A (ja) | 膵嚢胞性線維症の予防および/または対症治療のための医薬組成物 | |
JP5091474B2 (ja) | フドステインと抗コリン薬を含有する医薬組成物 | |
JP2003511410A (ja) | 肥満症の治療のためのモルホリノール誘導体 | |
Rozanski et al. | Advances in respiratory therapy | |
WO2007040188A1 (ja) | 杯細胞過形成抑制のための医薬組成物 | |
JP2009007332A (ja) | アゼラスチン類とエフェドリン類を含有する医薬組成物 | |
JP5463019B2 (ja) | エピナスチン類とエフェドリン類とを含有する気道杯細胞過形成を抑制するための医薬組成物 | |
Wolfson et al. | Accidental subcutaneous remifentanil infusion as a cause of delayed awakening after craniotomy | |
JP2010150242A (ja) | アンレキサノクスとエフェドリン類を含有する経口用医薬組成物 | |
US20240108601A1 (en) | Treatment of mental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125845 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1125845 Country of ref document: HK |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20120926 |